1. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012
2. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC);Kim;ASCO Meeting Abstracts,2012
3. Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer;Shaw;Ann Oncol,2013
4. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). ASCO Annual Meeting. 2011:Abstract CRA7506
5. Biomarkers are here to stay for clinical research and standard care;Bunn;J Thorac Oncol,2010